NCT02888743 2026-03-18
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
89 trialsNCT01266642 2026-03-11
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02125786 2026-02-24
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT01946529 2026-02-23
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT03822897 2026-02-17
EVADER
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT01750073 2025-11-18
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
Phase 2 Active not recruiting
NCT03747419 2025-10-31
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03786783 2025-10-09
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00924027 2025-09-05
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00334815 2025-08-24
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04409002 2025-08-15
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT05691829 2025-07-29
IRRADIATE-Lung
NYU Langone Health
Phase 2 Terminated
NCT03944915 2025-05-11
DEPEND
University of Chicago
Phase 2 Completed
NCT03085719 2025-02-25
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT03486197 2024-11-20
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
University of Washington
Phase 2 Terminated
NCT02258659 2024-09-24
OPTIMA
University of Chicago
Phase 2 Completed
NCT02773238 2024-08-14
FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
University of Washington
Phase 2 Completed
NCT03139916 2024-05-16
Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Massachusetts General Hospital
Phase 2 Completed
NCT02830594 2024-02-20
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Completed
NCT04690855 2023-12-04
TARA
Hoosier Cancer Research Network
Phase 2 Terminated
NCT01307956 2023-10-26
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
Phase 2 Terminated
NCT03649841 2023-10-26
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
Phase 2 Terminated
NCT05110781 2023-09-05
Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site
University of California, Davis
Phase 2 Terminated
NCT03421652 2023-08-04
Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT03595228 2023-04-14
BN Brachyury and Radiation in Chordoma
Bavarian Nordic
Phase 2 Completed
NCT03043807 2023-02-16
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00100802 2023-02-15
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Children's Oncology Group
Phase 2 Completed
NCT03617913 2023-01-06
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
Phase 2 Completed
NCT01410344 2022-12-08
BMT CTN 0903
Medical College of Wisconsin
Phase 2 Completed
NCT03087019 2022-10-14
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02716974 2022-08-04
oligo-mets
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00855803 2022-03-16
Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT00193427 2022-03-03
Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02805179 2021-04-15
A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02641691 2021-02-18
NORMAL-R
Washington University School of Medicine
Phase 2 Completed
NCT02064582 2020-10-12
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT00736944 2020-09-09
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
Washington University School of Medicine
Phase 2 Completed
NCT01370213 2020-05-13
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01787006 2020-03-10
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
University Hospital Schleswig-Holstein
Phase 2 Completed
NCT01449279 2020-03-02
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
Stanford University
Phase 2 Completed
NCT00522795 2020-02-17
Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)
Brown University
Phase 2 Completed
NCT02538471 2019-12-09
LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT01886105 2019-10-29
Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT01182350 2019-09-04
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00126555 2019-08-30
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00343083 2019-08-19
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
University of Maryland, Baltimore
Phase 2 Completed
NCT00027846 2019-08-07
Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
Children's Oncology Group
Phase 2 Completed
NCT00321685 2019-03-27
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00611858 2019-01-08
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated